Back

Kazia Therapeutics advances paxalisib into Phase 2 colorectal cancer trials

Verifying
  • Kazia Therapeutics is advancing paxalisib into Phase 2 colorectal cancer trials.
  • The company recently raised $40 million to support its cancer-drug development plans.
  • Kazia Therapeutics is also planning a new breast cancer study.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.